Press release
Post- Polycythemia Vera Myelofibrosis (PPV-MF) Market Outlook 2025: Innovations, Treatments, and Global Industry Trends | Most Leading Companies - Celgene Corp, Italfarmaco SpA, NS Pharma Inc, Gilead Sciences Inc and MEI Pharma Inc.
Post- Polycythemia Vera Myelofibrosis (PPV-MF) Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/post-polycythemia-vera-myelofibrosis-market?kb
United States: Recent Industry Developments
✅ KRT-232 (Kartos Therapeutics): Currently undergoing Phase 2/3 trials for TP53-wild-type patients with relapsed/refractory PPV-MF, this oral MDM2 inhibitor aims to offer a novel treatment option.
✅ PXS-5505 (Syntara): In Phase 1/2a trials, this pan-lysyl oxidase inhibitor is being evaluated for its potential to reverse bone marrow fibrosis in PPV-MF patients. Claight Corp
✅ Rusfertide (Protagonist Therapeutics & Takeda): In late-stage trials, this hepcidin mimetic has shown promise in reducing the need for phlebotomies and alleviating symptoms like fatigue and itching in PPV-MF patients.
Europe: Recent Industry Developments
✅ Calreticulin-targeted therapies: Emerging as potential treatments, these therapies aim to address the underlying mechanisms of PPV-MF and are being explored in clinical trials.
Asia-Pacific: Recent Industry Developments
✅ Type II JAK inhibitors: These novel agents are being investigated as add-on therapies to existing treatments, potentially offering improved outcomes for PPV-MF patients.
Key Players:
AbbVie Inc, JW Pharmaceutical Corp, F. Hoffmann-La Roche Ltd, Celgene Corp, Italfarmaco SpA, Merck & Co Inc, Novartis AG, NS Pharma Inc, Gilead Sciences Inc and MEI Pharma Inc.
Growth Forecast Projected:
The Global Post- Polycythemia Vera myelofibrosis Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Post- Polycythemia Vera myelofibrosis Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=post-polycythemia-vera-myelofibrosis-market
Key Segments:
By Type: (Durvalumab, Givinostat, Glasdegib, Idelalisib, IMG-7289, Others)
By Application: (Hospital, Clinic, Others)
Regional Analysis for Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.
Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.
Chapter 3: Offers an in-depth look at the competitive landscape among Post- Polycythemia Vera myelofibrosis producers, including revenue shares, strategic moves, and recent mergers and acquisitions.
Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.
Chapters 5 & 6: Analyze Post- Polycythemia Vera myelofibrosis revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.
Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.
Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.
Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.
Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.
Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/post-polycythemia-vera-myelofibrosis-market?kb
FAQ's
Q1: How fast is the Post- Polycythemia Vera myelofibrosis Market growing?
A: The Market is on an impressive growth trajectory, expected to expand at a CAGR from 2025 to 2032
Q2: Which regions are dominating the Post- Polycythemia Vera myelofibrosis Market and which are fastest-growing?
A: North America dominating the Post- Polycythemia Vera myelofibrosis market.
Have any Enquiry of This Report@ https://www.datamintelligence.com/enquiry/post-polycythemia-vera-myelofibrosis-market?kb
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Post- Polycythemia Vera Myelofibrosis (PPV-MF) Market Outlook 2025: Innovations, Treatments, and Global Industry Trends | Most Leading Companies - Celgene Corp, Italfarmaco SpA, NS Pharma Inc, Gilead Sciences Inc and MEI Pharma Inc. here
News-ID: 4223434 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Physician Dispensed Cosmeceuticals Market to Reach US$ 69.84 Billion by 2033 at …
The physician dispensed cosmeceuticals market reached US$ 36.55 billion in 2024 and is projected to reach US$ 69.84 billion by 2033, growing at a CAGR of 7.8% during the forecast period 2025-2033, according to the DataM Intelligence report. Market growth is primarily driven by increasing consumer preference for clinically proven, dermatologist-recommended skincare products that address concerns such as aging, acne, hyperpigmentation, and sensitive skin. Rising awareness of skin health, coupled…
Point-of-Care Ultrasound Market to Reach US$ 4.60 Billion by 2033 at 8.8% CAGR; …
The point-of-care ultrasound (POCUS) market reached US$ 1.99 billion in 2023, increased to US$ 2.16 billion in 2024, and is projected to reach US$ 4.60 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033. Market expansion is driven by the growing need for rapid, accurate, and bedside diagnostic imaging across emergency care, critical care, anesthesiology, cardiology, and primary care settings. The shift toward decentralized healthcare…
Procurement as a Service Market to Reach US$ 16.74 Billion by 2033 at 10.4% CAGR …
The global Procurement as a Service (PaaS) market reached US$ 6.30 billion in 2023, increased to US$ 6.87 billion in 2024, and is expected to reach US$ 16.74 billion by 2033, growing at a CAGR of 10.4% during the forecast period 2025-2033. Market growth is driven by rising demand from manufacturing, automotive, electronics, and healthcare industries for scalable, cost-efficient procurement solutions. Organizations are increasingly adopting PaaS to streamline sourcing, supplier…
Precision Potentiometers Market Set for Strong Growth to USD 2.30 Billion by 203 …
The Global Precision Potentiometers Market reached USD 1.40 billion in 2023 and is expected to reach USD 2.30 billion by 2031, growing with a CAGR of 6.3% during the forecast period 2024-2031.
Market growth is driven by rising demand for high-accuracy sensing in electronics, automotive electronics, and industrial automation. Advancements in miniaturization, integration with IoT devices, expanding applications in aerospace and medical devices, and growing emphasis on precision instrumentation are further…
More Releases for Polycythemia
Polycythemia Vera Market Massive Growth opportunity Ahead
Polycythemia Vera Market Outlook 2024-2034: Rising Diagnosis Rates and Advancements in Targeted Therapies to Drive Growth
Introduction
Polycythemia Vera (PV) is a rare chronic myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells, and in some cases, white blood cells and platelets. This leads to increased blood viscosity, higher risk of thrombosis, fatigue, headaches, and splenomegaly. PV is primarily associated with mutations in the JAK2 gene, which has shaped the…
Polycythemia Vera Pipeline: 10+ Therapies in Development by Pharma Giants Poised …
The Polycythemia Vera (PV) treatment landscape is undergoing significant evolution, driven by leading biopharmaceutical companies such as Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, and Perseus Proteomics. With JAK inhibitors like ruxolitinib already established, the focus has now shifted to next-generation therapeutics targeting disease-modifying mechanisms, cytokine signaling pathways, and novel erythropoiesis regulation. These therapies aim to reduce thrombotic risk, alleviate symptom burden, and delay progression to myelofibrosis.
DelveInsight's "Polycythemia Vera - Pipeline Insight,…
Polycythemia Clinical Trials, Drugs, Key Companies, Polycythemia Treatment Marke …
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight.
Polycythemia Overview:
Polycythemia, also known as erythrocytosis, is characterized by an increase in red blood cell mass, which is typically identified through laboratory tests showing elevated hemoglobin and hematocrit levels. Polycythemia vera is a specific type of polycythemia, marked by the…
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period.
The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On…
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On…
Polycythemia Vera Therapeutics Market to See Incredible Growth During 2021 – 2 …
Polycythemia Vera Therapeutics Market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of +4% over the forecast period (2021-2029).
Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases.…
